Search

Your search keyword '"Neumann, F"' showing total 4 results
Start Over Author "Neumann, F" Region united states
4 results on '"Neumann, F"'

1. The effective corporate audit committee.

Author

Mautz, R. K. and Neumann, F. L.

Subjects
AUDIT committees, COMMITTEES, AUDITING of corporations, CORPORATE directors, INTERNAL auditing, ORGANIZATIONAL structure, CORPORATE finance, CORPORATE governance, MANAGERIAL accounting
Abstract

The financial debacles of some well-known companies during the past year have troubled many directors and other policy-making executives. Could such calamities have been prevented by some means--or, at least, was there some way of giving responsible officers more advance warning of financial difficulty? Not surprisingly, interest is growing in such organizational devices as the corporate audit committee. This article presents the findings of a large-scale research project on audit committee operations in industry. Audit committees are not as common as many observers think, the study shows. But they have proved quite effective if staffed and organized in appropriate ways, and the claimed advantages for outside directors, corporate executives, and CPAs have been borne out in corporate experience. [ABSTRACT FROM AUTHOR]

Published
1970

2. Medicine--Pro & Con.

Author

LEE, SIDNEY S., BROWN, DOUGLAS A., KOOP, CHESTER S., SPANG, A. JAMES, JONES, PERRY T., PERETSMAN, JACOB, GUTTMACHER, RICHARD M., and NEUMANN, F. K.

Subjects
MEDICAL care costs, HOSPITAL costs, HOSPITAL prospective payment, PHYSICIANS, HEALTH insurance
Abstract

Several letters to the editor are presented in response to an article in the March 15, 1968 issue about the rising health care costs in the U.S. and the role that hospitals and physicians play in it.

Published
1968

3. The Function of Telomere Clustering in Yeast: The Circe Effect.

Author

Gasser, S. M., Hediger, F., Taddei, A., Neumann, F. R., and Gartenberg, M. R.

Subjects
*TELOMERES, *YEAST, *CONFERENCES & conventions, *VARIEGATION, *CHROMATIN
Abstract

Highlights a study on the function of telomere clustering in yeast that was presented at the 69th Cold Spring Harbor Symposia on Quantitative Biology in the U.S. in 2004. Genetic diversity through telomere-associated variegation; Ability of silent chromatin to direct its own anchorage of a chromosomal context; Strain construction and yeast techniques.

Published
2004
Full Text
View/download PDF

4. Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.

Author

Levy M, Xie L, Wang Y, Neumann F, Srivastava S, Naranjo D, Xu J, Zhang Q, and Dalal M

Subjects
Cardiovascular Diseases pathology, Female, Humans, Incidence, Male, Middle Aged, Risk Factors, Treatment Outcome, United States, Aniline Compounds adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cardiovascular Diseases chemically induced, Imidazoles adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Nitriles adverse effects, Protein Kinase Inhibitors adverse effects, Pyridazines adverse effects, Quinolines adverse effects
Abstract

Introduction: In this real-world study, the incidence of cardiovascular events (CV) including major adverse cardiac events (MACE), arterial occlusive events (AOE), and venous occlusive events (VOE) was evaluated in chronic myeloid leukemia (CML) patients treated with ponatinib or bosutinib in a US commercial database population., Materials and Methods: CML patients aged ≥18 years with use of 1 or 2 prior tyrosine kinase inhibitors prescribed bosutinib or ponatinib were selected from the IBM® MarketScan® Research database. Cox proportional hazard model analyses were conducted to examine any difference in CV event risk., Results: Ponatinib and bosutinib was associated with similar incidence and risk of CV events, including MACEs (HR: 1.02; 95% CI: 0.35, 3.01), AOEs (HR: 0.90; 95% CI: 0.43, 1.85) and VOEs (HR: 0.92; 95% CI: 0.44, 1.94)., Conclusion: Treatment with ponatinib or bosutinib was not associated with significant differences in the incidence of CV events in CML patients., (Copyright © 2021. Published by Elsevier Ltd.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results